BACK OF THE BOOK
pASHions
When I started pediatric residency and
my pediatric hematology/oncology fellow-
ship, though, the hours were grueling, so
dance took a backseat. I still tried to go to
ballet classes whenever I could.
When I finished my first year as a
fellow, I had more time and started per-
forming again. When I was in high school,
I could never in a million years have pre-
dicted that I would still be performing, but
I did for several years.
Now that you run your own lab, do
you practice ballet in your spare
time?
I do, but it’s been several years since
I’ve performed. I still go to the stu-
dio when I can, and I’m not the only
researcher there. In Boston, there is
a community of “dancing doctors.” I
remember one dancer from Germany
with whom I was doing a pas de
deux; right before we went on stage,
he said, “Kim, I want to talk to you
about polymerase chain reaction.” He
had a master’s degree in biology, so
we would talk about science between
rehearsals.
What performances are you most
proud of?
I am very proud of my time with José
Mateo’s company. We performed in
a beautiful old theater in downtown
Boston and I absolutely love The
Nutcracker. There’s a holiday spirit
around that piece, and I have such
intense childhood memories of see-
ing it.
More recently, I worked with Liz
Lapuh, a ballet teacher and chore-
ographer at the Dance Complex in
Cambridge. She loves to choreograph
pas de deux pieces, and we were able
to choreograph some original pieces
with my dance partner. It was won-
derful to be actively involved in that
creative process.
Do your kids express any interest in
following in your footsteps? (Pun
intended.)
Full disclosure: I did not want either
of my children to do gymnastics.
But, when my son was in kinder-
garten, he went to a birthday party
at a gymnastics school. The coach
of the boy’s team was running the
party and it quickly became clear
that he was auditioning my son for
the team! The coach came to me
after the party and asked about
bringing him on to the team, but I
pushed it off for a while. My son,
however, kept asking about it. So,
we brought him to a gymnastics
camp in the summer and that was
it. He has been doing gymnastics
ever since. He’s 13 now and a level
9 gymnast. He travels around the
country for some of his meets, and
52
ASH Clinical News
just qualified for the 2019 Men’s Junior
Olympics National Championships.
And with my daughter, I did what my
mother did for me: We put her in ballet
classes, but she said it was boring! She
is exploring other dance styles and did
Junior Olympics gymnastics. Her sports
passion, however, is soccer. She plays for
academy and travel teams in the Boston
area.
Is there any overlap between the skills
you use in dancing and those that you
apply in your career?
Definitely! Thinking about pas de deux
dances, it’s a partnership. To be success-
ful, you have to work well with someone; if
you’re trying to do a lift and you and your
partner aren’t in sync, it’s not going to
work. It’s the same if you’re working col-
laboratively in the lab.
I also think both medicine and ballet
CALQUENCE ® (acalabrutinib) capsules, for oral use
Initial U.S. Approval: 2017
Brief Summary of Prescribing Information. For full Prescribing Information consult official
package insert.
INDICATIONS AND USAGE
CALQUENCE is indicated for the treatment of adult patients with mantle cell lymphoma (MCL)
who have received at least one prior therapy.
This indication is approved under accelerated approval based on overall response rate [see
Clinical Studies (14) in the full Prescribing Information]. Continued approval for this indication
may be contingent upon verification and description of clinical benefit in confirmatory trials.
DOSAGE AND ADMINISTRATION
Recommended Dosage
The recommended dose of CALQUENCE is 100 mg taken orally approximately every twelve
hours until disease progression or unacceptable toxicity.
Advise patients to swallow capsule whole with water. Advise patients not to open, break or
chew the capsules. CALQUENCE may be taken with or without food. If a dose of CALQUENCE
is missed by more than 3 hours, it should be skipped and the next dose should be taken at
its regularly scheduled time. Extra capsules of CALQUENCE should not be taken to make up
for a missed dose.
Dose Modifications
Adverse Reactions
Recommended dose modifications of CALQUENCE for Grade 3 or greater adverse reactions
are provided in Table 1.
Table 1: Recommended Dose Modifications for Adverse Reactions
Adverse Reaction Dose Modification
Occurrence
(Starting dose = 100 mg twice daily)
Grade 3 or greater
Interrupt CALQUENCE.
non-hematologic toxicities,
First and Second Once toxicity has resolved to Grade 1 or
baseline level, CALQUENCE therapy may
Grade 3 thrombocytopenia
be resumed at 100 mg twice daily.
with bleeding,
Grade 4
Interrupt CALQUENCE.
thrombocytopenia
Once toxicity has resolved to Grade 1 or
Third
or
baseline level, CALQUENCE therapy may
be resumed at 100 mg daily.
Grade 4 neutropenia
lasting longer than
Fourth
Discontinue CALQUENCE.
7 days
Event
Adverse reactions graded by the National Cancer Institute Common Terminology Criteria for Adverse
Events (NCI CTCAE) version 4.03.
Dose Modifications for Use with CYP3A Inhibitors or Inducers
Recommended dose modifications are described below [see Drug Interactions (7) in the full
Prescribing Information].
CYP3A
Inhibition
Induction
Co-administered Drug
Recommended CALQUENCE use
Avoid concomitant use.
If these inhibitors will be used short-term
Strong CYP3A inhibitor
(such as antiinfectives for up to seven days),
interrupt CALQUENCE.
Moderate CYP3A inhibitor 100 mg once daily.
Avoid concomitant use.
Strong CYP3A inducer
If these inducers cannot be avoided, increase
CALQUENCE dose to 200 mg twice daily.
Concomitant Use with Gastric Acid Reducing Agents
Proton Pump Inhibitors: Avoid concomitant use [see Drug Interactions (7) in the full
Prescribing Information].
H2-Receptor Antagonists: Take CALQUENCE 2 hours before taking a H2-receptor antagonist
[see Drug Interactions (7) in the full Prescribing Information].
Antacids: Separate dosing by at least 2 hours [see Drug Interactions (7) in the full
Prescribing Information].
CONTRAINDICATIONS
None.
WARNINGS AND PRECAUTIONS
Hemorrhage
Serious hemorrhagic events, including fatal events, have occurred in the combined safety
database of 612 patients with hematologic malignancies treated with CALQUENCE
monotherapy. Grade 3 or higher bleeding events, including gastrointestinal, intracranial,
and epistaxis have been reported in 2% of patients. Overall, bleeding events including
bruising and petechiae of any grade occurred in approximately 50% of patients with
hematological malignancies.
The mechanism for the bleeding events is not well understood. CALQUENCE may further
increase the risk of hemorrhage in patients receiving antiplatelet or anticoagulant therapies
and patients should be monitored for signs of bleeding. Consider the benefit-risk of
withholding CALQUENCE for 3-7 days pre- and post-surgery depending upon the type of
surgery and the risk of bleeding.
Infection
Serious infections (bacterial, viral or fungal), including fatal events and opportunistic
infections have occurred in the combined safety database of 612 patients with hematologic
malignancies treated with CALQUENCE monotherapy. Consider prophylaxis in patients who
are at increased risk for opportunistic infections.
are highly disciplined. Both involve a lot of
effort and diligent work toward an end goal
– whether it’s a presentation or a perfor-
mance. I enjoy that process, and there’s a
magic that takes over when it all comes to-
gether. On the stage we’re working toward
perfection, but in the lab that’s not exactly
the endpoint. A different excitement takes
over when we’re working doggedly on an
experiment and then the data come back
and the “answer” is revealed! ●
Grade 3 or higher infections occurred in 18% of these patients. The most frequently reported
Grade 3 or 4 infection was pneumonia. Infections due to hepatitis B virus (HBV) reactivation
and progressive multifocal leukoencephalopathy (PML) have occurred. Monitor patients for
signs and symptoms of infection and treat as medically appropriate.
Cytopenias
In the combined safety database of 612 patients with hematologic malignancies, patients
treated with CALQUENCE monotherapy experienced Grade 3 or 4 cytopenias, including
neutropenia (23%), anemia (11%) and thrombocytopenia (8%) based on laboratory
measurements. In the CALQUENCE clinical Trial LY-004, patients’ complete blood counts
were assessed monthly during treatment.
Second Primary Malignancies
Second primary malignancies, including non-skin carcinomas, have occurred in 11% of
patients with hematologic malignancies treated with CALQUENCE monotherapy in the
combined safety database of 612 patients. The most frequent second primary malignancy
was skin cancer, reported in 7% of patients. Advise protection from sun exposure.
Atrial Fibrillation and Flutter
In the combined safety database of 612 patients with hematologic malignancies treated with
CALQUENCE monotherapy, atrial fibrillation and atrial flutter of any grade occurred in 3%
of patients, and Grade 3 in 1% of patients. Monitor for atrial fibrillation and atrial flutter and
manage as appropriate.
ADVERSE REACTIONS
The following adverse reactions are discussed in greater detail in other sections of
the labeling:
• Hemorrhage [see Warnings and Precautions (5.1) in the full Prescribing Information]
• Infection [see Warnings and Precautions (5.2) in the full Prescribing Information]
• Cytopenias [see Warnings and Precautions (5.3) in the full Prescribing Information]
• Second Primary Malignancies [see Warnings and Precautions (5.4) in the full Prescribing
Information]
• Atrial Fibrillation and Flutter [see Warnings and Precautions (5.5) in the full Prescribing
Information]
Clinical Trials Experience
As clinical trials are conducted under widely varying conditions, adverse reaction rates
observed in the clinical trials of a drug cannot be directly compared to rates in the clinical
trials of another drug and may not reflect the rates observed in practice.
The safety data described in this section reflect exposure to CALQUENCE (100 mg twice
daily) in 124 patients with previously treated MCL in Trial LY-004 [see Clinical Studies (14)
in the full Prescribing Information]. The median duration of treatment with CALQUENCE
was 16.6 (range 0.1 to 26.6) months. A total of 91 (73.4%) patients were treated with
CALQUENCE for ≥ 6 months and 74 (59.7%) patients were treated for ≥ 1 year.
The most common adverse reactions (≥ 20%) of any grade were anemia, thrombocytopenia,
headache, neutropenia, diarrhea, fatigue, myalgia, and bruising. Grade 1 severity for
the non-hematologic, most common events were as follows: headache (25%), diarrhea
(16%), fatigue (20%), myalgia (15%), and bruising (19%). The most common Grade ≥ 3
non-hematological adverse reaction (reported in at least 2% of patients) was diarrhea.
Dose reductions or discontinuation due to any adverse reaction were reported in 1.6% and
6.5% of patients, respectively.
Tables 2 and 3 present the frequency category of adverse reactions observed in patients with
MCL treated with CALQUENCE.
Table 2: Non-Hematologic Adverse Reactions* in ≥ 5% (All Grades) of Patients with MCL
in Trial LY-004
Body System
Adverse Reactions
CALQUENCE 100 mg twice daily
N=124
All Grades (%)
Grade ≥ 3 (%)
Nervous system disorders
Headache
39
Gastrointestinal disorders
Diarrhea
31
Nausea
19
Abdominal pain
15
Constipation
15
Vomiting
13
General Disorders
Fatigue
28
Musculoskeletal and connective tissue disorders
Myalgia
21
Skin & subcutaneous tissue disorders
Bruising †
21
Rash †
18
Vascular disorders
8
Hemorrhage/Hematoma †
Respiratory, thoracic & mediastinal disorders
Epistaxis
6
1.6
3.2
0.8
1.6
-
1.6
0.8
0.8
-
0.8
0.8
-
* Per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.03.
†
Bruising: Includes all preferred terms (PTs) containing ‘bruise,’ ‘contusion,’ ‘petechiae,’ or ‘ecchymosis’
Rash: Includes all PTs containing ‘rash’
Hemorrhage/hematoma: Includes all PTs containing ‘hemorrhage’ or ‘hematoma’